News

Approved In The U.S. And In Europe,Extended Storage Provides Enhanced Convenience for Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Paris, France and Jerusalem, Israel, June 6, 2007 - Teva Pharmaceutical Industries, Ltd. and sanofi-aventis announced today that the application for up to one month room temperature storage of COPAXONE® (glatiramer acetate injection) pre-filled syringe has been approved by the U.S. Food and Drug Administration (FDA) and in Europe under the Mutual Recognition Procedure (MRP). With this supplemental amendment, COPAXONE® may now be stored by patients at roo Read More »

Jerusalem, Israel, July 11, 2008 - Teva believes that COPAXONE® (glatiramer acetate injection) will remain a proprietary, market-leading product for the reduction of relapses in patients with relapsing-remitting multiple sclerosis (RRMS). The Company's intellectual property estate, regulatory filings worldwide and technical and scientific leadership should ensure that COPAXONE® continues to provide a novel, safe and efficacious approach to managing the disease for the foreseeable future. Although attempts may be made, Teva anticipates minimal risk for generic competition over the product Read More »

Jerusalem, Israel, April 12, 2010 - Teva Pharmaceutical Industries, Ltd. (NASDAQ:TEVA) announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA). "This milestone underscores the established long-term efficacy and safety of Copaxone® to physicians and patients who rely on the therapy to manage MS," said Kenneth Johnson M.D., professor of neurology, Unive Read More »